Immunicum AB (publ) (Nasdaq Stockholm: IMMU.ST)

https://www.immunicum.com

Immunicum AB (publ) develops cancer immune primers for the treatment of tumor diseases. A phase II clinical trial for the Company's most advanced product - INTUVAX® against kidney cancer - has been initiated. The project portfolio contains additional clinical phase I/II studies in liver cancer and in gastrointestinal stromal tumors (GIST). *

	Start	2002-01-01 splitoff
	End	2022-06-23 renamed
	Group	Mendus (Group)
	Today	Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST)
	Successor	Mendus AB (publ) (Nasdaq Stockholm: IMMU.ST)
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	Intuvax®
	Person	Rohmann, Sven (Immunicum 202011 CEO before Biotech Pharmacon 200810– VP BusDev before Novartis Pharma)
	Person 2	Zeilemaker, Sijme (Immunicum 201703– Director Business Development before InteRNA Technologies + to-BBB Technologies)

	Region	Göteborg (Gothenburg)
	Country	Sweden
	Street	2 Grafiska Vägen
	City	41263 Göteborg
	Tel	+46-31-415052
		Address record changed: 2020-12-02

Basic data	Employees	B: 11 to 50 (2018-12-31)
	Currency	SEK
	Annual sales	184,000 (income, operating (2018) 2018-12-31)
	Profit	-97,860,000 (2018-12-31)
	Cash	443,798,000 (2018-12-31)

		* Document for »About Section«:

		Record changed: 2024-02-12